



**PENTACHLOROPHENOL
AND SOME RELATED
COMPOUNDS**

VOLUME 117

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 4–11 October 2016

LYON, FRANCE - 2019

**IARC MONOGRAPHS
ON THE EVALUATION
OF CARCINOGENIC RISKS
TO HUMANS**

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	7
A. GENERAL PRINCIPLES AND PROCEDURES	7
1. Background.....	7
2. Objective and scope.....	8
3. Selection of agents for review	9
4. Data for the <i>Monographs</i>	10
5. Meeting participants	10
6. Working procedures.....	11
B. SCIENTIFIC REVIEW AND EVALUATION	12
1. Exposure data.....	13
2. Studies of cancer in humans.....	14
3. Studies of cancer in experimental animals.....	18
4. Mechanistic and other relevant data.....	21
5. Summary	24
6. Evaluation and rationale.....	25
References.....	29
GENERAL REMARKS	31
PENTACHLOROPHENOL	33
1. Exposure Data.....	33
1.1 Identification of the agent	33
1.2 Production and use.....	34
1.3 Analytical methods	37
1.4 Occurrence and exposure.....	37
1.5. Regulations and guidelines	48

2. Cancer in Humans	53
2.1 Cohort studies	53
2.2 Case-control studies	59
2.3 Exposure assessment and biological markers in epidemiological studies.....	65
3. Cancer in Experimental Animals	68
3.1 Mouse	68
3.2 Rat	76
4. Mechanistic and Other Relevant Data	77
4.1 Absorption, distribution, metabolism, and excretion.....	77
4.2 Mechanisms of carcinogenesis.....	83
4.3 Data relevant to comparisons across agents and end-points	103
4.4 Susceptibility	118
4.5 Other adverse effects	118
5. Summary of Data Reported	119
5.1 Exposure data.....	119
5.2 Human carcinogenicity data	119
5.3 Animal carcinogenicity data	121
5.4 Mechanistic and other relevant data.....	121
6. Evaluation.....	123
6.1 Cancer in humans.....	123
6.2 Cancer in experimental animals.....	123
6.3 Overall evaluation	123
6.4 Rationale	123
References.....	124
2,4,6-TRICHLOROPHENOL	141
1. Exposure Data.....	141
1.1 Identification of the agent	141
1.2 Production and use.....	142
1.3 Analytical methods	142
1.4 Occurrence and exposure.....	143
1.5 Regulations and guidelines	147
2. Cancer in Humans	147
2.1 Cohort studies	147
2.2 Case-control studies	150
2.3 Exposure assessment in epidemiological studies.....	151
3. Cancer in Experimental Animals	152
3.1 Mouse	152
3.2 Rat	155
4. Mechanistic and Other Relevant Data	155
4.1 Absorption, distribution, metabolism, and excretion.....	155
4.2 Mechanisms of carcinogenesis.....	158
4.3 Data relevant to comparisons across agents and end-points	161
4.4 Cancer susceptibility data	162
4.5 Other adverse effects.....	162

5. Summary of Data Reported	162
5.1 Exposure data	162
5.2 Human carcinogenicity data	162
5.3 Animal carcinogenicity data	163
5.4 Mechanistic and other relevant data	163
6. Evaluation	163
6.1 Cancer in humans	163
6.2 Cancer in experimental animals	163
6.3 Overall evaluation	163
References	164
3,3',4,4'-TETRACHLOROAZOBENZENE	169
1. Exposure Data	169
1.1 Identification of the agent	169
1.2 Production and use	169
1.3 Methods of analysis	170
1.4 Occurrence and exposure	170
1.5. Regulations and guidelines	171
2. Cancer in Humans	171
3. Cancer in Experimental Animals	171
3.1 Mouse	171
3.2 Rat	175
4. Mechanistic and Other Relevant Data	176
4.1 Absorption, distribution, metabolism, and excretion	176
4.2 Mechanisms of carcinogenesis	180
4.3 Data relevant to comparisons across agents and end-points	185
4.4 Cancer susceptibility data	185
4.5 Other adverse effects	185
5. Summary of Data Reported	186
5.1 Exposure data	186
5.2 Human carcinogenicity data	186
5.3 Animal carcinogenicity data	186
5.4 Mechanistic and other relevant data	186
6. Evaluation	187
6.1 Cancer in humans	187
6.2 Cancer in experimental animals	187
6.3 Overall evaluation	188
6.4 Rationale	188
References	188
ALDRIN AND DIELDRIN	193
1. Exposure Data	193
1.1 Identification of the agents	193
1.2 Production and use	194
1.3 Analytical methods	196
1.4 Occurrence and exposure	197

1.5. Regulations and guidelines	207
2. Cancer in Humans	207
2.1 Aldrin	207
2.2 Dieldrin	223
2.3 Exposure assessment in epidemiological studies of aldrin and dieldrin	237
3. Cancer in Experimental Animals	239
3.1 Aldrin	239
3.2 Dieldrin	247
4. Mechanistic and Other Relevant Data	275
4.1 Absorption, distribution, metabolism, and excretion	275
4.2 Mechanisms of carcinogenesis	282
4.3 Data relevant to comparisons across agents and end-points	301
4.4 Cancer susceptibility	301
4.5 Other adverse effects	301
5. Summary of Data Reported	301
5.1 Exposure data	301
5.2 Human carcinogenicity data	302
5.3 Animal carcinogenicity data	303
5.4 Mechanistic and other relevant data	304
6. Evaluation	306
6.1 Cancer in humans	306
6.2 Cancer in experimental animals	306
6.3 Overall evaluation	306
6.4 Rationale	306
References	306
LIST OF ABBREVIATIONS	323
ANNEX 1. SUPPLEMENTAL MATERIAL	325